Die adjuvante Chemotherapie des nicht-kleinzelligen Lungenkarzinoms

Jahrbuch Statistik Austria 2010. Chansky K, Sculier JP, Crowley J, Giroux D, Van Meerbeeck J, Goldstraw P. On behalf of the international staging committee and participating institutions; the international association for the study of lung cancer staging project: prognostic factors and pathologic tnm stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009;4:792–801. Non-small cell lung cancer collaborative group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J. 1995;311:899–909. Scagliotti GV, Fossati R, Torri V,et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or stage IIIA non-small cell lung cancer. J Natl Cancer Inst. 2003;95(19):1453–61. The international adjuvant lung cancer trial collaborative group. N Engl J Med. 2004;350:351–60. Le Chevalier T et al; ASCO 2008, Abstract 7507. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based Chemotherapy in Resected Lung Cancer. J Clin Oncol. 2010;28:35–42. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26:173–82. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–97. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR.10. J Clin Oncol 2010;28:29–34. Douillard JV, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association, ANITA): a randomised controlled trial. Lancet Oncol. 2006;7:719–27. Strauss GM, Herndon JE, Maddaus M, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage ib non-small-cell lung cancer: calgb 9633 with the cancer and leukemia group b, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol. 2008;26:5043–51. Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol. 2005;23:4999–5006. NSCLC Meta-analyses collaborative group; adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. The Lancet. 2010;375:1267–77. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26:1–7. Douillard JV, Tribodet H, Aubert D, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer. Subgroup analysis of the adjuvant cisplatin evaluation. J Thorac Oncol. 2010;5:220–8. Pepe C, Hasan B, Winton T, et al. Adjuvant vinorelbine and cisplatin in elderly patients: national cancer institute of canada and intergroup study JBR.10. J Clin Oncol. 2007;25:1553-61. Goss GD, Lorimer I, Tsao MS, et al. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. J Clin Oncol. 2010;28:18s (suppl; abstr LBA7005).